Realcan Pharmaceutical Group Co., Ltd. (002589) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Realcan Pharmaceutical Group Co., Ltd.

Why is Realcan Pharmaceutical Group Co., Ltd. ?

Poor Management Efficiency with a low ROCE of 2.78%

The company has been able to generate a Return on Capital Employed (avg) of 2.78% signifying low profitability per unit of total capital (equity and debt)

High Debt Company with a Debt to Equity ratio (avg) at times

Poor long term growth as Net Sales has grown by an annual rate of -24.27% and Operating profit at -146.51% over the last 5 years
High Debt Company with a Debt to Equity ratio (avg) at times
The company has been able to generate a Return on Equity (avg) of 2.68% signifying low profitability per unit of shareholders funds

Poor long term growth as Net Sales has grown by an annual rate of -24.27% and Operating profit at -146.51% over the last 5 years

Negative results in Mar 25

NET PROFIT(9M) At CNY -26.14 MM has Grown at -148.11%
NET SALES(Q) Lowest at CNY 1,747.16 MM
INTEREST(Q) Highest at CNY 75.53 MM

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -11.28%, its profits have fallen by -98.6%
At the current price, the company has a high dividend yield of 0.5

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Realcan Pharmaceutical Group Co., Ltd. for you?

Medium Risk, High Return

Absolute

Risk Adjusted

Volatility

Realcan Pharmaceutical Group Co., Ltd.

17.99%

0.94

29.09%

China Shanghai Composite

14.77%

1.01

15.10%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-24.27%

EBIT Growth (5y)

-146.51%

EBIT to Interest (avg)

0.22

Debt to EBITDA (avg)

33.16

Net Debt to Equity (avg)

0.45

Sales to Capital Employed (avg)

0.60

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

80.29%

Pledged Shares

Institutional Holding

ROCE (avg)

2.78%

ROE (avg)

2.68%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

2827

Industry P/E

Price to Book Value

0.61

EV to EBIT

-138.14

EV to EBITDA

38.06

EV to Capital Employed

0.74

EV to Sales

0.81

PEG Ratio

Dividend Yield

0.50%

ROCE (Latest)

-0.54%

ROE (Latest)

0.02%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Bullish

Dow Theory

Mildly Bullish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

9What is working for the Company

PRE-TAX PROFIT(Q)

At CNY 24.28 MM has Grown at 779.09%

NET PROFIT(Q)

At CNY 14.91 MM has Grown at 694.94%

RAW MATERIAL COST(Y)

Fallen by -41.32% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at 44.75 %

DEBTORS TURNOVER RATIO(HY)

Highest at 1.44%

-10What is not working for the Company

NET PROFIT(9M)

At CNY -26.14 MM has Grown at -148.11%

NET SALES(Q)

Lowest at CNY 1,747.16 MM

INTEREST(Q)

Highest at CNY 75.53 MM

Here's what is working for Realcan Pharmaceutical Group Co., Ltd.

Pre-Tax Profit

At CNY 24.28 MM has Grown at 779.09%

over average net sales of the previous four periods of CNY 2.76 MM

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (CNY MM)

Net Profit

At CNY 14.91 MM has Grown at 694.94%

over average net sales of the previous four periods of CNY -2.51 MM

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (CNY MM)

Debt-Equity Ratio

Lowest at 44.75 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Debtors Turnover Ratio

Highest at 1.44%

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by -41.32% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Realcan Pharmaceutical Group Co., Ltd.

Net Sales

At CNY 1,747.16 MM has Fallen at -11.86%

over average net sales of the previous four periods of CNY 1,982.36 MM

MOJO Watch

Near term sales trend is very negative

Net Sales (CNY MM)

Interest

At CNY 75.53 MM has Grown at 178.1%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Net Sales

Lowest at CNY 1,747.16 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (CNY MM)

Interest

Highest at CNY 75.53 MM

in the last five periods and Increased by 178.1% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)